Biotheranostics Settles False Claims Allegations With DOJ for $2M

Apr 20, 2018

|

NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biotheranostics Settles False Claims Allegations With DOJ for $2M

To read the full story....

Breaking News

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

FDA-Led Group Evaluates Performance of RUO Liquid Biopsy Assays to Inform Practice Guidelines

4D Path Prepping FDA Submission for AI-Enabled Breast Cancer Digital Pathology Product

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

Sponsorships